These findings represent a significant advancement over previously reported data by providing further validation of SIL204's efficacy in the more clinically relevant orthotopic setting ...

This study is the first systematic evaluation of SIL-204 administered subcutaneously in orthotopic pancreatic cancer models, focusing on its ability to reduce primary tumor growth and metastatic ...